CRBU
Caribou Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.57
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.0M | 11.2M | 10.0M | 34.5M | 13.9M |
| Cost of Revenue | 23.1M | 3.6M | 3.9M | 3.5M | 3.6M |
| Gross Profit | (13.0M) | 7.5M | 6.1M | 31.0M | 10.2M |
| Operating Expenses | |||||
| R&D Expense | 85.8M | 109.4M | 130.2M | 112.1M | 82.2M |
| SG&A Expense | 33.7M | 37.9M | 46.5M | 38.5M | 38.0M |
| General & Admin Expense | 33.7M | 37.9M | 46.5M | 38.5M | 38.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (23.1M) | (3.6M) | (3.9M) | (3.5M) | (3.6M) |
| Total Operating Expenses | 96.5M | 143.7M | 172.7M | 147.0M | 116.6M |
| Cost and Expenses | 119.5M | 147.4M | 176.6M | 150.5M | 120.3M |
| Operating Income (EBIT) | (109.5M) | (136.2M) | (166.6M) | (116.1M) | (106.4M) |
| Non-Operating | |||||
| Interest Income | — | 8.0M | — | 10.7M | 4.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | 8.0M | — | 10.7M | 4.6M |
| Other Non-Op Income/Expense | 5.5M | (12.5M) | 17.5M | 14.2M | 7.0M |
| Non-Operating Income (excl Interest) | (3.4M) | 12.5M | (17.5M) | (14.2M) | (7.0M) |
| EBT (Pre-Tax Income) | (104.0M) | (148.7M) | (149.1M) | (101.9M) | (99.4M) |
| Income Tax Expense | (550.0K) | (550.0K) | (9.0K) | 193.0K | 70.0K |
| Bottom Line | |||||
| Net Income | (103.4M) | (148.1M) | (149.1M) | (102.1M) | (99.4M) |
| Earnings from Cont. Ops | (103.4M) | (148.1M) | (149.1M) | (102.1M) | (99.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (103.4M) | (148.1M) | (149.1M) | (102.1M) | (99.4M) |
| Per Share | |||||
| Basic EPS | ($1.08) | ($1.59) | ($1.65) | ($1.38) | ($1.64) |
| Diluted EPS | ($1.08) | ($1.59) | ($1.65) | ($1.38) | ($1.64) |
| Revenue Per Share | $0.10 | $0.12 | $0.11 | $0.47 | $0.23 |
| Shares | |||||
| Basic Shares Outstanding | 101.0M | 93.4M | 90.3M | 73.8M | 60.8M |
| Diluted Shares Outstanding | 101.0M | 93.4M | 90.3M | 73.8M | 60.8M |
| Profitability Metrics | |||||
| EBITDA | (104.1M) | (145.0M) | (145.2M) | (98.4M) | (95.7M) |
| D&A | 2.0M | 3.6M | 3.9M | 3.5M | 3.6M |
| EBIT | (106.1M) | (148.7M) | (149.1M) | (101.9M) | (99.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026